ArticleNature communications2026

Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy.

Sonia Jiménez-Vázquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.